Estimating the risk of re-emergence after stopping polio vaccination

Frontiers in Microbiology

Volumn 3, Issue MAY, 2012, Pages

  Sasaki, Akira ^a,b   Haraguchi, Yoshihiro ^c   Yoshida, Hiromu ^d  

^a GRADUATE UNIVERSITY FOR ADVANCED STUDIES   (Japan)

^b INTERNATIONAL INSTITUTE FOR APPLIED SYSTEMS ANALYSIS   (Austria)

^c KYUSHU UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Branching process; Demographic stochasticity; Epidemiological dynamics; Live vaccination; Poliovirus; Risk of re emergence; Silent circulation; Vaccine derived strain

Indexed keywords

EID: 84875774694     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2012.00178     Document Type: Article

References (49)

1. Abraham, R., Minor, P., Dunn, G., Mod-lin, J., and Ogra, P. (1993). Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J. Infect. Dis. 168, 1105-1109.
2. Alexander, J. P. Jr., Gary, H. E. Jr., and Pallansch, M. A. (1997). Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J. Infect. Dis. 175(Suppl. 1), S176-S182.
3. American Academy of Pediatrics Committee on Infectious Diseases. (1999). Poliomyelitis prevention: revised recommendations for use of inactivated and live oral poliovirus vaccines. Pediatrics 103, 171-172.
4. Anderson,R. M.,and May,R. M. (1982). Directly transmitted infections diseases: control by vaccination. Science 215, 1053-1060.
5. Anderson, R. M., and May, R. M. (1991). Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press.
6. Benyesh-Melnick, M., Melnick, J. L., Rawls, W. E., Wimberly, I., Oro, J. B., Ben-Porath, E., and Rennick, V. (1967). Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am. J. Epidemiol. 86, 12-136.
7. Centers for Disease Control and Prevention. (2000). Public health dispatch: Outbreak of poliomyelitis dominican Republic and Haiti,2000. JAMA 49, 1094-1103.
8. Centers for Disease Control and Prevention. (2001). Circulation of a type 2 vaccinederived poliovirus Egypt, 1982-1993. MMWR Morb. Mortal. Wkly. Rep. 50, 41-42.
9. Dunn, G., Begg, N. T., Cammack, N., and Minor, P. D. (1990). Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J. Med. Virol. 32, 92-95.
10. Eichner, M., and Dietz, K. (1996). Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Am. J. Epidemiol. 143, 816-822.
11. Eichner, M., and Hadeler, K. P. (1995). Deterministic models for the eradication of poliomyelitis: vaccination with the inactivated (IPV) and attenuated (OPV) polio virus vaccine. Math. Biosci. 127, 149-166.
12. Fine, P. E. M., and Carneiro, I. A. M. (1999). Transmissibility and persistence of oral polio vaccine virus: Implications for the global poliomyelitis eradication initiative. Am. J. Epidemiol. 150, 1001-1021.
13. Gelfand, H. M., Potash, L., Leblanc, D. R., and Fox, J. P. (1959). "Revised preliminary report on the Louisiana observation of the natural spread within families of living vaccine strains of poliovirus," in Live Poliovirus Vaccines, Volume Scientific Publication No. 44, ed. C. H. StuartHarris (Washington, DC: Pan American Sanitary Bereau), 203-217.
14. Ghendon, Y., and Robertson, S. E. (1994). Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull. World Health Organ. 72, 973-983.
15. Hara, M., Saito, Y., Komatsu, T., Kodama, H., Abo, W., Chiba, S., and Nakao, T. (1981). Antigenic analysis of polioviruses isolated from a child with a gammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiol. Immunol. 25, 905-913.
16. Haraguchi, Y., and Sasaki, A. (1997). Evolutionary pattern of intrahost pathogen antigenic drift: Effect of cross-reactivity in immune response. Philos. Trans. R. Soc. Lond. B Boil. Sci. 352, 11-20.
17. Henry, J. L., Jaikaran, E. S., Davies, J. R., Tomlinson,A. J., Mason, P. J., Barnes, J. M., and Beale, A. J. (1966). A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J. Hyg. (Lond.) 64, 105-120.
18. Iwai, M., Takizawa, T., Nakayama, T., Matsuura, K., Yoshida, H., Hasegawa, S., Obara, M., Horimoto, E., Kurata, T., and Horie, H. (2008). Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccinederived poliovirus type 1, 2, 3 strains in Japan. Scand. J. Infect. Dis. 40, 247-253.
19. Kew, O. M., Sutter, R. W., Nottay, B. K., Mcdonough, M. J., Prevots, D. R., Quick, L., and Pallansch, M. A. (1998). Prolonged replication of a type 1 vaccinederived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36, 2893-2899.
20. Laassri, M., Lottenbach, K., Belshe, R., Rennels, M., Plotkin, S., and Chumakov, K. (2006). Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. J. Infect. Dis. 193, 1344-1349.
21. Lipsitch, M. (1997). Vaccination against colonizing bacteria with multiple serotypes. Proc. Natl. Acad. Sci. U.S.A. 94, 6571-6576.
22. Marker Test Subcommittee. The Japan Live Poliovaccine Research Commission. (1967). Evaluation of Sabin live poliovirus vaccine in Japan. IV. Maker tests on poliovirus strains recovered from vaccinees and their contacts. Jpn. J. Med. Sci. Biol. 20, 167-173.
23. Martinez, C., Old, M. O., Kwock, D. K., Khan, S. S., Garcia, J. J., Chan, C. S., and Webster, R., Falkovitz-Halpern,M. S.,and Maldonado,Y. A. (2004). Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. J. Infect. Dis. 190, 409-416.
24. Matsuura, K., Ishikura, M., Yoshida, H., Nakayama, T., Hasegawa, S., Ando, S., Horie, H., Miyamura, T., and Kitamura, T. (2000). Assessment of poliovirus eradication in Japan: Genomic analysis of the polioviruses isolated from the river water and the sewage in Toyama prefecture. Appl. Environ. Microbiol. 66, 5087-5091.
25. Mclean, A. R. (1995). Vaccination, evolution and changes in the efficacy of vaccines a theoretical framework. Proc. Biol. Sci. 261, 389-393.
26. Minor, P. D. (1992). The molecular biology of poliovaccines. J. Gen. Virol. 73, 3065-3077.
27. Minor, P. D., Dunn, G., Ramsay, M. E., and Brown, D. (2005). Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J. Med. Virol. 75, 153-160.
28. Miyamura, K.,Yamashita, K.,Yamadera, S., Kato, N., Akatsuka, M., Hara, M., Inouye, S., and Yamazaki, S. (1992). Poliovirus surveillance: isolation of polioviruses in Japan, 1980-1991 A report of the National Epidemiological Surveillance of Infectious Agents in Japan. Jpn. J. Med. Sci. Biol. 45, 203-214.
29. Murdin, A. D., Barreto, L., and Plotkin, S. (1996). Inactivated poliovirus vaccine: past and present experience. Vaccine 14, 735-746.
30. Nowak, M. A., Anderson, R. M., Mclean, A. R., Wolfs, T. F. W., Goudsmit, J., and May, R. M. (1991). Antigenic diversity thresholds and the development of AIDS. Science 254, 963-969.
31. Nowak, M. A., and May, R. M. (1991). Mathematical biology of HIV infection: antigenic variation and diversity threshold. Math. Biosci. 106, 1-21.
32. Nowak, M. A., and May, R. M. (2000). Viral Dynamics. Oxford: Oxford University Press.
33. Patriarca, P. A., Sutter, R. W., and Oostvogel, P. M. (1997). Outbreaks of paralytic poliomyelitis, 19761995. J. Infect. Dis. 175(Suppl. 1), S165-172.
34. Patriarca, P. A., Wright, P. F., and John, T. J. (1991). Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis. 13, 926-939
35. Plotkin, S., Orenstein, W., and Offit, P. (2008). Vaccine, 5th Edn. Saunders: Elsevier, 647-650.
36. Poyry, T., Stenvik, M., and Hovi, T. (1988). Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland. Appl. Environ. Microbiol. 54, 371-374.
37. Sasaki, A. (1994). Evolution of antigen drift/switching continuously evading pathogens. J. Theor. Biol. 168, 291-308.
38. Sasaki, A., and Haraguchi, Y. (2000). Antigenic drift of viruses within a host: a finite site model with demographic stochasticity. J. Mol. Evol. 51, 245-255.
39. Shulman, L. M., Manor, Y., Handsher, R., Delpeyroux, F., Mcdonough, M. J., Halmut, T., Silberstein, I., Alfandari, J., Quay, J., Fisher, T., Robinov, J., Kew, O. M., Crainic, R., and Mendelson, E. (2000). Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J. Clin. Microbiol. 38, 3729-3734.
40. Sutter, R. W., Suleiman, A., Malankar, P., Al-Khusaiby, S., Mehta, F., Clements, G. B., Pallansch, M. A., and Robertson, S. E. (2000). Trial of a supplemental dose of four poliovirus vaccines. New Engl. J. Med. 343, 767-773.
41. Triki, H., Abdallah, M. V., Ben Aissa, R., Bouratbine, A., Ben Ali Kacem, M., Bouraoui, S., Koubaa, C., Zouari, S., Mohsni, E., Crainic, R., and Dellagi, K. (1997). Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants. Vaccine 15, 1123-1129.
42. Vaccine Administration Subcommittee. The Japan Live Poliovaccine Research Commission. (1966). Evaluation of Sabin live poliovirus vaccine in Japan. II. Clinical, virologic and immunologic effects of vaccine in children. Jpn. J. Med. Sci. Biol. 19, 277-291.
43. Wassilak,S.,Pate,M. A.,Wannemuehler, K., Jenks, J., Burns, C., Chenoweth, P., Abanida, E. A., Adu, F., Baba, M., Gasasira, A., Iber, J., Mkanda, P., Williams, A. J., Shaw, J., Pallansch, M., and Kew, O. (2011). Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J. Infect. Dis. 203, 898-909.
44. Wiegers, K., Uhlig, H., and Dernick, R. (1989). N-AgIB of poliovirus type 1: a discontinuous epitope formed by two loops of VP1 comprising residues 96-104 and 141-152. Virology 170, 583-586.
45. Wood, D. J., Sutter, R. W., and Dowdle, W. R. (2000). Stopping poliovirus vaccination after eradication: issues and challenges. Bull. World Health Orang. 78, 347-357.
46. World Health Organization. (1989). Report of a WHO sponsored meeting. Primary immunodeficiency diseases. Immunodefic. Rev. 1, 173-205.
47. World Health Organization. (2010). Global Polio Eradication Initiative Strategic Plan 2010-2012. Available at: http://www.polioeradication.org/Portals/0/Document/StrategicPlan/ StratPlan2010_2012_ENG.pdf
48. Yoshida, H., Horie, H., Matsuura, K., and Miyamura, T. (2000). Characterisation of vaccine-derived polioviruses isolated from sewage and river water in Japan. Lancet 356, 1461-1463.
49. Zdrazilek, J., Drasnar, M., Hlavova, H., Jadrnickova, E., Jandasek, L., Kasova, V., Koza, J., Matyasova, I., Uvizl, M., Valihrach, J., and Weigen-dova, J. (1982). Presence of polioviruses and other enteral viruses in sewage: a survey in the Czech Socialistic Republic 1969-1976. J. Hyg. Epidemiol. Microbiol. Immunol. 26, 1-14.